Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.79
-0.0500-0.64%
Post-market: 7.78-0.0103-0.13%19:59 EDT
Volume:7.62M
Turnover:59.32M
Market Cap:8.26B
PE:-7.88
High:7.95
Open:7.85
Low:7.60
Close:7.84
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.99
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-7.89
PE(LYR):-20.39

Loading ...

Immunitybio Inc - Idmc Confirms Study With 366 Patients Adequately Powered to Detect Difference in Complete Response Rate

THOMSON REUTERS
·
Mar 26

Immunitybio Inc - on Track to Submit Supplemental Bla in 2026

THOMSON REUTERS
·
Mar 26

Immunitybio Confirms Statistical Power in Pivotal Randomized Bcg-NaÏVe Nmibc Trial to Detect Clinically Meaningful Differences Between Anktiva® Plus Bcg Versus Bcg Alone; Supplemental Bla Submission on Track for 2026

THOMSON REUTERS
·
Mar 26

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 25

Top Midday Decliners

MT Newswires Live
·
Mar 25

“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26%

TIPRANKS
·
Mar 25

BRIEF-US FDA Sends Warning Letter To Immunitybio For "False Or Misleading" TV Ad And Podcast On Anktiva

Reuters
·
Mar 24

BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials

Reuters
·
Mar 24

Immunitybio: Intend to Respond to FDA Within Requested Timeframe and Work Cooperatively With Agency to Address Matters Raised in Letter

THOMSON REUTERS
·
Mar 24

Immunitybio- Take FDA’s Concerns Seriously and Have Initiated a Review of Letter With Legal and Regulatory Teams

THOMSON REUTERS
·
Mar 24

Immunitybio- Acknowledges Receipt of Opdp Letter Dated March 13, Regarding Some Promotional Materials for AnktivaÒ (Nogapendekin Alfa Inbakicept-Pmln)

THOMSON REUTERS
·
Mar 24

Option traders moderately bearish in ImmunityBio with shares down 22.61%

TIPRANKS
·
Mar 24

ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad

Reuters
·
Mar 24

ImmunityBio Down Nearly 20%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

Dow Jones
·
Mar 24

US FDA: Sends Warning Letter to Immunitybio, Inc for "False or Misleading" Tv Ad and Podcast on Anktiva

THOMSON REUTERS
·
Mar 24

US FDA : Immunitybio Ads "Misleadingly" Claims Anktiva Can Cure, Prevent All Cancer-Website

THOMSON REUTERS
·
Mar 24

ImmunityBio falls -23.0%

TIPRANKS
·
Mar 24

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 23

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Mar 23

ImmunityBio Gains First Asian ANKTIVA Nod As Cell Therapy Story Builds

Simply Wall St.
·
Mar 22